沃森生物(300142.SZ)：冻干带状疱疹病毒mRNA疫苗临床试验申请获得受理

Core Viewpoint - Watson Bio's subsidiary has applied for clinical trials of a freeze-dried mRNA vaccine for herpes zoster, which has been accepted by the National Medical Products Administration [1] Group 1 - The vaccine is developed in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals [1] - The mRNA vaccine technology platform is independently developed by Watson Bio and its partners [1] - The vaccine aims to stimulate the immune system to produce immunity against the herpes zoster virus for prevention purposes [1]